DD262582A5 - Ifosfamid-lyophilisat und verfahren zu dessen herstellung - Google Patents

Ifosfamid-lyophilisat und verfahren zu dessen herstellung Download PDF

Info

Publication number: DD262582A5
Authority: DD; German Democratic Republic
Prior art keywords: ifosfamide; solution; weight; hexitol; drying
Prior art date: 1986-10-31

Application number

DD87308471A

Other languages

German (de)

English (en)

Inventor

Dieter Sauerbier

Uwe-Peter Dammann

Otto Isaac

Original Assignee

��@��@��k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-10-31

Filing date

1987-10-30

Publication date

1988-12-07

1987-10-30 Application filed by ��@��@��k�� filed Critical ��@��@��k��

1988-12-07 Publication of DD262582A5 publication Critical patent/DD262582A5/de

Links

HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 title claims abstract description 68
229960001101 ifosfamide Drugs 0.000 title claims abstract description 67
238000000034 method Methods 0.000 title claims abstract description 10
238000004519 manufacturing process Methods 0.000 title description 5
FBPFZTCFMRRESA-UHFFFAOYSA-N hexane-1,2,3,4,5,6-hexol Chemical compound OCC(O)C(O)C(O)C(O)CO FBPFZTCFMRRESA-UHFFFAOYSA-N 0.000 claims abstract description 18
238000002360 preparation method Methods 0.000 claims abstract description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
239000000546 pharmaceutical excipient Substances 0.000 abstract description 5
230000018044 dehydration Effects 0.000 abstract 1
238000006297 dehydration reaction Methods 0.000 abstract 1
230000008014 freezing Effects 0.000 abstract 1
238000007710 freezing Methods 0.000 abstract 1
229940124531 pharmaceutical excipient Drugs 0.000 abstract 1
239000000243 solution Substances 0.000 description 40
238000002347 injection Methods 0.000 description 24
239000007924 injection Substances 0.000 description 24
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 19
238000011049 filling Methods 0.000 description 17
238000004108 freeze drying Methods 0.000 description 17
235000010355 mannitol Nutrition 0.000 description 14
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
229930195725 Mannitol Natural products 0.000 description 11
239000000594 mannitol Substances 0.000 description 10
238000001035 drying Methods 0.000 description 8
239000011521 glass Substances 0.000 description 8
238000003860 storage Methods 0.000 description 8
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 6
239000007864 aqueous solution Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 5
238000004090 dissolution Methods 0.000 description 5
FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 5
239000002904 solvent Substances 0.000 description 5
229960002920 sorbitol Drugs 0.000 description 5
238000001914 filtration Methods 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
238000004140 cleaning Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
239000011148 porous material Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
ZZVDXRCAGGQFAK-UHFFFAOYSA-N 2h-oxazaphosphinine Chemical class N1OC=CC=P1 ZZVDXRCAGGQFAK-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-UNTFVMJOSA-N L-iditol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)CO FBPFZTCFMRRESA-UNTFVMJOSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000013543 active substance Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000011109 contamination Methods 0.000 description 2
-1 cyclophosphamide Chemical compound 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000000203 mixture Substances 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
235000002639 sodium chloride Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000011146 sterile filtration Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
FBPFZTCFMRRESA-OMMKOOBNSA-N L-altritol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)[C@@H](O)CO FBPFZTCFMRRESA-OMMKOOBNSA-N 0.000 description 1
FBPFZTCFMRRESA-BXKVDMCESA-N L-mannitol Chemical compound OC[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)CO FBPFZTCFMRRESA-BXKVDMCESA-N 0.000 description 1
229930182842 L-mannitol Natural products 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
238000005273 aeration Methods 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000012459 cleaning agent Substances 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000002845 discoloration Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
230000005496 eutectics Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000012792 lyophilization process Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000002245 particle Substances 0.000 description 1
150000003014 phosphoric acid esters Chemical class 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000011045 prefiltration Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000005245 sintering Methods 0.000 description 1
238000000859 sublimation Methods 0.000 description 1
230000008022 sublimation Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000004383 yellowing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oil, Petroleum & Natural Gas (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Dermatology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Cephalosporin Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Control Of El Displays (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Amplifiers (AREA)
Indole Compounds (AREA)

DD87308471A 1986-10-31 1987-10-30 Ifosfamid-lyophilisat und verfahren zu dessen herstellung DD262582A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3637089		1986-10-31

Publications (1)

Publication Number	Publication Date
DD262582A5 true DD262582A5 (de)	1988-12-07

Family

ID=6312873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD87308471A DD262582A5 (de)	1986-10-31	1987-10-30	Ifosfamid-lyophilisat und verfahren zu dessen herstellung

Country Status (25)

Country	Link
EP (1)	EP0265812B1 (da)
JP (1)	JPS63159319A (da)
KR (1)	KR900003491B1 (da)
AT (1)	ATE55250T1 (da)
AU (1)	AU598602B2 (da)
CA (1)	CA1314231C (da)
DD (1)	DD262582A5 (da)
DE (1)	DE3764235D1 (da)
DK (1)	DK169308B1 (da)
EG (1)	EG18333A (da)
ES (1)	ES2017982B3 (da)
FI (1)	FI87140C (da)
GE (1)	GEP19971025B (da)
GR (1)	GR3000708T3 (da)
HU (1)	HU197987B (da)
IL (1)	IL84312A (da)
IN (1)	IN168119B (da)
LV (1)	LV10051B (da)
MX (1)	MX8958A (da)
NO (1)	NO873860L (da)
PT (1)	PT86032B (da)
RU (1)	RU1836079C (da)
UA (1)	UA11075A (da)
YU (1)	YU197387A (da)
ZA (1)	ZA878183B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE58900183D1 (de) *	1988-03-19	1991-08-29	Asta Pharma Ag	Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5227373A (en) *	1991-10-23	1993-07-13	Bristol-Myers Squibb Co.	Lyophilized ifosfamide compositions
WO1995007083A1 (en) *	1993-09-10	1995-03-16	F.H. Faulding & Co. Limited	Ifosfamide lyophilisate composition
DE19529057B4 (de) *	1995-08-08	2007-12-13	Baxter Healthcare S.A.	Ifosfamid-Lyophilisat-Zubereitungen
BR9908479A (pt) *	1998-03-03	2000-12-05	Shionogi & Co	Composições farmacêuticas que contêm o inibidor de fosfolipase [[3-(2-amino-1,2-dioxoetil)-2-etil-1-(fenilmetil_-1h-indol- 4-il]óxil] acetato de sódio
WO2004022699A2 (en) *	2002-09-05	2004-03-18	Bharat Serums And Vaccines Ltd.	Liquid stable composition of oxazaphosphorine with mesna
CN100463678C (zh) *	2002-12-02	2009-02-25	印度血清及疫苗有限公司	用于肠胃外给药的异环磷酰胺组合物及其制备方法
US8436190B2 (en) *	2005-01-14	2013-05-07	Cephalon, Inc.	Bendamustine pharmaceutical compositions
PL2071917T3 (pl) *	2006-09-29	2013-04-30	Infa Sa	System opakowaniowy dla kompozycji farmaceutycznych oraz zestaw do podawania dożylnego
WO2016087001A1 (en) *	2014-12-04	2016-06-09	Huawei Technologies Co., Ltd.	Load allocation in a data communication network

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3732340A (en) *	1966-07-11	1973-05-08	Asta Werke Ag Chem Fab	N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) *	1977-05-09	1978-11-16	Walton J Smith	Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
EP0083439B1 (de) *	1981-12-31	1989-07-26	ASTA Pharma AG	4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
US4537883A (en) *	1982-11-12	1985-08-27	Mead Johnson & Company	Lyophilized cyclophosphamide

1987
- 1987-09-15 NO NO873860A patent/NO873860L/no unknown
- 1987-10-20 DE DE8787115322T patent/DE3764235D1/de not_active Expired - Lifetime
- 1987-10-20 ES ES87115322T patent/ES2017982B3/es not_active Expired - Lifetime
- 1987-10-20 AT AT87115322T patent/ATE55250T1/de not_active IP Right Cessation
- 1987-10-20 EP EP87115322A patent/EP0265812B1/de not_active Expired - Lifetime
- 1987-10-23 MX MX895887A patent/MX8958A/es unknown
- 1987-10-26 IN IN837/CAL/87A patent/IN168119B/en unknown
- 1987-10-27 FI FI874727A patent/FI87140C/fi not_active IP Right Cessation
- 1987-10-28 EG EG61687A patent/EG18333A/xx active
- 1987-10-29 JP JP62272002A patent/JPS63159319A/ja active Granted
- 1987-10-29 PT PT86032A patent/PT86032B/pt unknown
- 1987-10-29 UA UA4203570A patent/UA11075A/uk unknown
- 1987-10-29 IL IL84312A patent/IL84312A/xx not_active IP Right Cessation
- 1987-10-29 RU SU874203570A patent/RU1836079C/ru active
- 1987-10-30 ZA ZA878183A patent/ZA878183B/xx unknown
- 1987-10-30 AU AU80529/87A patent/AU598602B2/en not_active Ceased
- 1987-10-30 HU HU874900A patent/HU197987B/hu unknown
- 1987-10-30 CA CA000550706A patent/CA1314231C/en not_active Expired - Lifetime
- 1987-10-30 DD DD87308471A patent/DD262582A5/de not_active IP Right Cessation
- 1987-10-30 YU YU01973/87A patent/YU197387A/xx unknown
- 1987-10-30 DK DK569687A patent/DK169308B1/da not_active IP Right Cessation
- 1987-10-30 KR KR1019870012077A patent/KR900003491B1/ko not_active Expired
1990
- 1990-08-09 GR GR90400533T patent/GR3000708T3/el unknown
1992
- 1992-10-27 LV LVP-92-174A patent/LV10051B/lv unknown
1993
- 1993-07-07 GE GEAP1993972A patent/GEP19971025B/en unknown

Also Published As

Publication number	Publication date
PT86032A (de)	1987-11-01
DK169308B1 (da)	1994-10-10
IL84312A (en)	1991-11-21
FI874727A0 (fi)	1987-10-27
UA11075A (uk)	1996-12-25
YU197387A (en)	1988-12-31
DK569687D0 (da)	1987-10-30
KR900003491B1 (ko)	1990-05-21
ZA878183B (en)	1988-05-02
ES2017982B3 (es)	1991-03-16
HUT44932A (en)	1988-05-30
ATE55250T1 (de)	1990-08-15
EG18333A (en)	1993-12-30
JPH0543684B2 (da)	1993-07-02
EP0265812A1 (de)	1988-05-04
LV10051A (lv)	1994-05-10
JPS63159319A (ja)	1988-07-02
GEP19971025B (en)	1997-04-06
NO873860L (no)	1988-05-02
DE3764235D1 (de)	1990-09-13
FI87140B (fi)	1992-08-31
DK569687A (da)	1988-05-01
FI874727L (fi)	1988-05-01
RU1836079C (ru)	1993-08-23
GR3000708T3 (en)	1991-10-10
EP0265812B1 (de)	1990-08-08
KR880004814A (ko)	1988-06-27
IL84312A0 (en)	1988-03-31
HU197987B (en)	1989-07-28
FI87140C (fi)	1992-12-10
NO873860D0 (no)	1987-09-15
IN168119B (da)	1991-02-09
PT86032B (pt)	1990-08-31
LV10051B (en)	1995-06-20
CA1314231C (en)	1993-03-09
AU8052987A (en)	1988-05-05
AU598602B2 (en)	1990-06-28
MX8958A (es)	1993-12-01

Legal Events

Date	Code	Title	Description
1997-08-14	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
EP0334083B1 (de)	1991-07-24	Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
DE60132108T2 (de)	2008-12-11	Gefriergetrocknetes pantoprazol-präparat und pantoprazol-injektion
DE69228105T2 (de)	1999-08-26	Verbesserte, gefriergetrocknete Ifosfamid-Zusammensetzungen
DE69628007T2 (de)	2003-11-27	Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
EP0941121B1 (de)	2004-09-22	Stabile lyophilisierte pharmazeutische zubereitungen von mono- oder polykonalen antikörpern
DE3729863A1 (de)	1989-03-16	Stabilisierte erythropoietin-lyophilisate
WO1989007934A1 (fr)	1989-09-08	Seringue a deux chambres contenant comme substance active une charge de proteine humaine a activite perissable
DE68904922T2 (de)	1993-06-03	Piroxicam in waessrigen loesungen enthaltende arzneizubereitungen und verfahren zu deren herstellung.
EP0265812B1 (de)	1990-08-08	Ifosfamid-Lyophilisat und Verfahren zu dessen Herstellung
US5204335A (en)	1993-04-20	Ifosfamide lyophilisate and process for its preparation
DE2752443C2 (de)	1983-07-14	Verfahren zur Herstellung von Cefazolin-Natrium
DE19529057B4 (de)	2007-12-13	Ifosfamid-Lyophilisat-Zubereitungen
EP0625908B1 (de)	1997-12-17	Antidot für hirudin und synthetische thrombininhibitoren
DE2920020C2 (da)	1988-09-01
DE2224182C2 (de)	1987-01-22	Verfahren zur Herstellung einer zum Sauerstofftransport befähigten, injizierbaren, wäßrigen, stabilen Emulsion
DE3907079A1 (de)	1989-09-28	Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung
DE3735614A1 (de)	1988-07-28	Ifosfamid-lyophilisat und verfahren zu dessen herstellung
EP1344521A1 (de)	2003-09-17	Verfahren zur Rekonstitution von lyophilisierten Proteinen
DE2262427A1 (de)	1973-07-12	Immunostimulierendes mittel und verfahren zu dessen herstellung
EP0591710A1 (de)	1994-04-13	Mesna-Injektionslösungen
WO1996017607A1 (de)	1996-06-13	Verfahren zur herstellung eines lyophilisats von pantoprazol
DE69231098T2 (de)	2000-09-14	Lyophilisierte zusammensetzung, die s(+)-4,4'-(1-methyl-1,2-ethandiyl)-bis(2,6-piperazindion)enthält
DE602005002742T2 (de)	2008-01-24	Verfahren zur stabilisierung von ungeordnetem cefovecin-natriumsalz
EP0684840B1 (de)	2000-08-23	Verfahren zur herstellung kolloidaler wässriger lösungen schwerlöslicher wirkstoffe und ein lipid dafür
DE19540132C2 (de)	2003-04-03	Ifosfamid-Lyophilisat